Lots of interesting abstracts and cases were submitted for TCTAP 2023. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-073
Angiogenesis Outcomes of Metformin Utilization in Diabetes Mellitus: A Systematic Review and Meta-Analysis
By Primasitha Maharany Harsoyo, Arisvia Sukma Hariftyani, Farah Aisha Shabrina, Annisya Dinda Paramitha, Saskia Ratna Desita, Hanestya Oky Hermawan, Asri Laksitarini, Annisa Trissatharra, Yudi Her Oktaviono
Presenter
Primasitha Maharany Harsoyo
Authors
Primasitha Maharany Harsoyo1, Arisvia Sukma Hariftyani2, Farah Aisha Shabrina2, Annisya Dinda Paramitha2, Saskia Ratna Desita2, Hanestya Oky Hermawan1, Asri Laksitarini2, Annisa Trissatharra2, Yudi Her Oktaviono1
Affiliation
General Regional Academic Hospital Dr. Soetomo, Universitas Airlangga, Indonesia1, Airlangga University, Indonesia2
View Study Report
TCTAP A-073
Cell Therapy and Angiogenesis
Angiogenesis Outcomes of Metformin Utilization in Diabetes Mellitus: A Systematic Review and Meta-Analysis
Primasitha Maharany Harsoyo1, Arisvia Sukma Hariftyani2, Farah Aisha Shabrina2, Annisya Dinda Paramitha2, Saskia Ratna Desita2, Hanestya Oky Hermawan1, Asri Laksitarini2, Annisa Trissatharra2, Yudi Her Oktaviono1
General Regional Academic Hospital Dr. Soetomo, Universitas Airlangga, Indonesia1, Airlangga University, Indonesia2
Background
Metformin has been shown to reduce cardiovascular risk in patients with type 2 diabetes mellitus, but the exact mechanism remains unclear. Proposed processes include angiogenesis modification and endothelial repair potentials. However, angiogenesis properties of metformin has been reported to be pleiotrophic.
Methods
We performed systematic review and meta-analysis conducted from MEDLINE, ScienceDirect, ProQuest, Web of Science, EBSCOhost, and Cochrane Library. The authors screened the articles based on inclusion criteria: (1) Diabetes mellitus type 2 patients; (2) Metformin as interventional therapy; (3) Human studies that have an angiogenesis endothelial marker as an outcome; (4) Written in English. Endothelial markers such as Vascular endothelial growth factor (VEGF), von-Wille-factor (vWf), plasminogen activator inhibitor-1 (PAI-1), soluble vascular adhesion molecule-1 (sVCAM-1), intercellular adhesion molecule-1 (ICAM-1), sE-selectin, tissue plasminogen activator (tPA), urinary albumin excretion (UAE), platelet endothelial cell adhesion molecule-1 (PECAM-1), and thrombin-activatable fibrinolysis inhibitor (TAFI) were assessed as angiogenesis outcomes.
Results
Seven randomized control trials (RCT) and one cross sectional study involving 1,119 patients were included. vWF (OR -0.28 [-0.50, -0.06]; p=0.01), sVCAM-1 (OR -0.33 [-0.46, -0.20]; p<0.00001), ICAM-1 (OR -0.25 [-0.38, -0.11]; p=0.0003), sE-selectin (OR -0.19 [-0.33, -0.05]; p = 0.007), and tPA (OR -0.62 [-0.88, -0.36]; p < 0.00001) were significantly reduced compared before and after metformin treatment using random effect methods.
Conclusion
Metformin has additional benefits in the improvement of endothelial function, as demonstrated by reduced antiangiogenic levels such as vWF, PAI-1, sVCAM-1, ICAM-1, sE-selectin, and tPA, after metformin treatment.